Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAPOVER: Signal Transduction Pathway Activity Analysis for Recurrent Ovarian Cancer Treatment
2020-005091-36Phase 4Terminated
- Sponsor
- Catharina Ziekenhuis
- Start
- May 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of letrozole, bicalutamide, everolimus and itraconazole in ovarian cancer, sponsored by Catharina Ziekenhuis. Primary endpoint: Progression-free survival ratio (PFS2/PFS1). Started May 2021; status: terminated.
02
Drugs
letrozolebicalutamideeverolimusitraconazole
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2020-005091-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005091-36.